A list of clinical trials with curcumin in
patients with different diseases
_________________________________________________________________________________________________________________________________________________
Disease Dose/Frequency Patients Response Reference
_________________________________________________________________________________________________________________________________________________
Safety trials
Phase
1 2000
mg/day1 10 Pipeline enhanced
bioavailability by 2000% Shoba et
al,1998
Phase-I 500-12,000
mg/day x 90 days 25 Histologic improvement of precancerous lesions4 Cheng
et al, 2001
Phase
1 500-12,000
mg/day 24 Safe, well-tolerated
even at 12 g/day Lao et al, 2006
Efficacy trials
Rheumatoid
arthritis 1200
mg/day x14 days 18 Improved symptoms Deodhar et al, 1980
Postoperative
inflammation 400 mg; 3
x/day x5 days 46 Decrease in
inflammation Satoskar et al, 1986
External
cancerous lesions 1%
ointment x several months 62 Reduction in smell In 90% pts, Kuttan et al, 1987
Reduction
of itching in all cases,
Dry lesions in 70% pts.
Reduction in lesion size & pain in 10% pts.
Cardiovascular 500
mg/day x 7 days 10 Decreased serum
lipid peroxidase (33%), Soni and
Kuttan, 1992
Increased
HDL cholesterol (29%),
Decreased
total serum cholesterol (12%)
HIV 625
mg; 4x/day x 56 days 40 Well tolerated James et al,1996
Gall
bladder function 20
mg, single dose (2 h) 12 Decreased gall
bladder volume Rasyid et al,1999
Chronic
anterior uveitis 375
mg; 3x /day x 84 days 32 86% decrease in
chronic anterior uveitis Lal et al,1999
Psoriasis 1%
curcumin gel 40 Decreased PhK2, TRR3, parakeratosis,
and Heng et al, 2000
density
of epidermal CD8+ T cells
Atherosclerosis 10 mg;
2x/day x 28 days 12 Lowered LDL and apoB,
Increased
HDL and ApoA Ramirez-Bosca et
al,2000
Idiopathic
Inflammatory Orbital 375
mg; 3x /day x 180-660 days 8 4 pts recovered
completely Lal et
al,2000
Pseudotumors 1
pt showed decrease in swelling
No
recurrence
Colorectal
cancer 36-180
mg/day x 120 days 15 Lowered GST Sharma et al, 2001
Human
gall bladder function 20-80
mg, single dose (2 hours) 12 Reduced
gall bladder volume by 50% Rasyid et al, 2002
Irritable
bowel syndrome 72-144 mg/day x 56 days 207 Reduced symptoms
Bundy et al, 2004
Colorectal
cancer 450-3600
mg/day x 120 days 15 Lowered
inducible serum PGE2 levels Sharma et al, 2004
Liver metastasis from CRC 450-3600 mg/day x 7 day 12 Low bioavailability Garcea
et al, 2004
Cadaveric
renal transplantation 480 mg;
x1-2/day x 30 days 43 Induced HO-1
activity Shoskes et al, 2005
Improved
early graft function
Tropical
pancreatitis 500
mg/day x 42 days 20 Improved symptoms Durgaprasad et
al, 2005
Inflammatory
bowel disease 550 mg; x
2-3/day x 60 days 10 Improved symptoms Holt et
al, 2005
Colorectal
cancer 450-3600
mg/day x 7 days 12 Decreased
M1G DNA adducts Garcea
et al, 2005
Ulcerative
colitis 2000
mg/day x 180 days 89 Maintains remission (how many) Hanai et
al, 2006
Improves cogenitive
function - 1010 Better MMSE score5 Ng et al, 2006
Familial adenomatous polyposis 480 mg; x3/day x 180 days 5 Reduces polyp numbers and volume Cruz-Correa et al, 2006 in FAP patients
____________________________________________________________________________________________________________
Notes:
1. + Piperine 20 mg/kg; 2, PhK:
Phosphorylase kinase; 3.TRR: keratinocyte
transferrin receptor ; 4. Histologic improvement of precancerous lesions was seen in
1 out of 2 patients with recently resected bladder
cancer, 2 out of 7 patients of oral leucoplakia, 1
out of 6 patients of intestinal metaplasia of the
stomach, I out of 4 patients with CIN and 2 out of 6 patients with Bowen's
disease; 5. MMSE: Mini-Mental State Examination Score.
A list of ongoing clinical trials with curcumin
in patients with different diseases
Disease Study
Type/Design Patients # Start Date Trial
Site
Colon cancer Phase-I, Randomized 24 Completed Univ. of
Michigan, Ann Arbor, USA
Colorectal cancer, ACF 1 Phase-I, Randomized2 - Suspended Rockefeller
University Hospital, New York, USA
Colon cancer Phase-III,
Randomized 100 March, 2006 Tel-Aviv Sourasky Medical Center,
Tel-Aviv, Israel
Colorectal cancer, ACF1 Phase-II,
Non-randomized 48 September, 2006 Univ. of Illinois, Chicago,
USA
FAP Phase-II,
Randomized4 68 July, 2005 Univ. of
Pennsylvania, Philadelphia, USA
FAP Phase-II, Non-randomized - November, 2005 Johns Hopkins Univesity,
Baltimore, USA
Aberrant crypt foci Prevention,
Randomized5 60 April, 2004 Cancer Institute
of New Jersey, New Brunswick, USA
Pancreatic cancer Phase-II,
Non-randomized6 45 July, 2004 Rambam Medcial Center, Haifa,
Israel
Pancreatic cancer Phase-II,
Non-randomized 50 November, 2004 M.D. Anderson Cancer
Center, Houston, USA
Pharmacokinetics Treatment,
Non-randomized 6 August, 2005 Massachusetts General
Hospital, Boston, USA
Myeodysplastic syndrome Phase II 30 Univ.
Massachusetts, Worcester, USA (Raza A)
Alzheimer’s disease Phase-II,
Randomized 33 July, 2003 Univ. of
California Los Angeles, Los Angeles, USA
Alzheimer’s disease Phase-I &II, Randomized7 30 Completed Chinese
University of Hong Kong, Shatin, Hong Kong
Multiple myeloma Randomized8 30 November, 2004 M.D. Anderson Cancer
Center, Houston, USA
Myelodysplastic syndrome Phase-I &II, Non-randomized9 50 December, 2006 Hadassah Medical Organization, Jerusalem,
Israel
Psoriasis Phase-II,
Non-randomized10 - October, 2005 Univ. of Pennsylvania,
Philadelphia, USA
Epilepsy Phase 1 ? ? AIIMS,
Delhi, India (Gupta YK)
Advanced HNSCC Phase II (1-8 g/day; 56 d) 40 ? Himalyan Instutute od Medical Sciences, India (Saini S)
HNSCC Phase II/III
DBRPC (3.6 g/day,bid) 300 ? AIIMS,
Delhi, India (Bahadur S/Ranju
R/Rath GK/Julka PK)
Cervical cancer
(Stage IIb,IIIb)Phase II/III
DBRPC (2 g/day,bid, 1 year) 100 ? AIIMS,
Delhi, India (Singh N/Jain SK/Rath GK/Julka PK)
Oral premalignant lesions Phase
II/III DBRPC (4 g/day,bidx
28 d) 90 ? Tata
Memorial Cancer Ctr, India (D’Cruz
A)
Oral premalignant lesions Phase
II/III DBRPC (3.6 g/day,bid) 96 Nov,
2006 Amrita
Institute, Kochi, India (Kuriakose MA)
Oral
leukoplakia Phase
II (curcumin gel, 3x/day, 6 mo) 100 ? Regional
cancer center, Trivan, India(Ramadas K, Pillai MR)
Gall bladder cancer Phase II (2-8 g/day) 60 ? BHU, India (Shukla VK)
Notes: 1. ACF; Abrerrant crypt foci
Trials were performed with curcumin in combination with 2. Quercetin2, sulindac; 2. Celecoxoib; 3. ACF; 4. Curcuminoids; 5. NSAIDs; 6. Gemcitabine; 6. Ginkgo extract; 7. Bioperine; 8. Coenzyme Q10; 10. Curcuminoids C3 complex; DBRPC, Double blind, randomized placebo-controlled